Cellectis reports Phase 1 data for leukemia therapy lasme-cel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- Nasdaq falls on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil down more than 4% on profit taking, report of China-backed push to end US-Iran fighting
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- Americold to wind down Ahold Delhaize facilities, take $305M charge
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Did Google and Tesla just break AI trade’s bull case?
Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL
October 16, 2025 3:19 PM EDTÂ Efficacy: ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9)
Safety:Â in Phase 1 (n=40), lasme-cel was generally well-tolerated (including 1 case of grade 2 IEC-HS which resolved)
Durability:Â in patients who achieved MRD-negative CR/CRi, median OS was 14.8 months
In the target Phase 2 population, CR/CRi rate of 56% with ~80% of patients achieving MRD-negative status
In the target Phase 2 population, 100% patients became transplant eligible with 78% proceeding to transplant
... More